Background: Regulatory T cell (Treg) based immunotherapy is a potential treatment for several immune disorders. By now, this approach proved successful in preclinical animal transplantation and auto-immunity models. In these models the success of Treg based immunotherapy crucially depends on the antigen-specificity of the infused Treg population. For the human setting, information is lacking on how to generate Treg with direct antigen-specificity ex vivo to be used for immunotherapy.
Introduction
Regulatory T cells (Treg) play a critical role in various immunological processes. These cells dampen immune responses, which is important in maintenance of (self-) tolerance and homeostasis. Immunotherapy based on Treg (either in vivo facilitation of Treg or infusion of ex vivo isolated / manipulated Treg) is therefore a potential treatment for many immune disorders. Such an approach has been proven successful in animal models of stem cell transplantation [1] [2] [3] [4] [5] [6] [7] , solid organ transplantation [8, 9] , auto-immunity [10] [11] [12] [13] [14] and even in infertility [15] . Treg therapy in human patients will require high cell numbers, which might be obtained by ex vivo expansion. It has been shown that human naturally occurring CD4 pos CD25 high Treg can be expanded polyclonally, by using anti-CD3 and anti-CD28 antibody stimulation in combination with IL-2 and/or IL-15 [16] [17] [18] [19] [20] [21] . These polyclonal expansion protocols greatly increase Treg numbers, while preserving suppressive capacity. However, there are some drawbacks regarding clinical application of polyclonally expanded Treg. First, since this type of activation encompasses Treg with a broad range of specificities, the infused polyclonal Treg may suppress immune responses other than the target response, thereby increasing the risk for opportunistic infections and tumor-growth. Second, due to the low percentage of Treg within a polyclonal cell pool that is specific for a given target antigen, large numbers of Treg need to be infused. These difficulties could be overcome by using antigen-specific Treg. In animal models, antigen-specific Treg have been shown to be far more efficient than polyclonal Treg [4, 6, 7, [12] [13] [14] . Even as few as 5610 3 antigen-specific Treg were sufficient to prevent the onset of diabetes in a NOD model [14] .
For the human setting, information is scarce on how to generate sufficient numbers of antigen-specific Treg ex-vivo from naturally occurring Treg [22] . The aim of this study was to design a successful strategy to obtain high numbers of Treg with direct alloantigen-specificity for use in transplantation settings. Based on previous findings, we hypothesized that it would be beneficial to combine polyclonal stimulation, to boost expansion, with alloantigen stimulation, to increase antigen-specificity. To test this hypothesis, we alternated these two stimulation methods in primary and secondary Treg expansion cycles and assessed cell numbers, phenotype, function and antigen-specificity before and after expansion. Thus, we succeeded in defining a protocol that yields high numbers of strictly alloantigen-specific human Treg.
Results

Optimal conditions for primary and secondary expansion cycles
With the objective to obtain the highest numbers of functionally active Treg with optimal direct alloantigen-specificity, we devised four expansion strategies, employing polyclonal and alloantigenspecific stimulation in two subsequent cycles of Treg expansion ( Figure 1 ). The cells that were obtained with these expansion strategies were compared in terms of absolute cell numbers, phenotype, suppressive capacity, antigen-specificity and anergy. Prior to analysis of the four selected Treg expansion strategies, individual expansion cycles were optimized, with regard to strength and mode of stimulation.
Cell sorting based on multiple surface markers such as CD25, CD127, CD62L and CD27 yields a high purity of FoxP3 pos Treg. However, these tools are not available for clinical grade purposes. Therefore, we specifically chose to use magnetic bead isolation for purification of Treg, as this most closely fits with the currently available GMP isolation tools. Cells isolated by this procedure expressed CD25 and FoxP3, but not CD127 (Figure 2A ), thus displaying a typical Treg phenotype [23] [24] [25] [26] . In contrast, CD4 pos CD25 neg conventional T cells (Tconv) did not express FoxP3 or CD25, and were positive for CD127. The majority of the isolated Treg as well as Tconv expressed the differentiation marker CD27, not its ligand CD70, and were positive for CD62L.
The freshly isolated Treg were hyporesponsive upon restimulation ( Figure 2B ) and able to suppress proliferation of autologous CD4 pos CD25 neg T cells upon stimulation with alloantigen ( Figure 2C , D and E), .50% suppression was seen with Tresp:Treg ratios of 4:1 or lower ( Figure 2C ). Tconv were not anergic, nor suppressive.
For alloantigen driven expansion, the optimal strength of alloantigen stimulation was determined by titrating irradiated HLA mismatched allogeneic PBMC into Treg cultures, in the presence of exogenous IL-2 and IL-15. In a primary MLR, proliferation was maximal with stimulator:responder ratios of 4:1 ( Figure 3A ). Secondary stimulation with alloantigen showed similar results ( Figure 3B ). The data shown in Figure 3B were obtained with Treg primed with alloantigen, but similar results were observed when polyclonally primed Treg were used (data not shown). Consequently, for expansion experiments, a stimulator:-responder ratio of 4:1 was used. Interestingly, a higher number of HLA-DRB1 mismatches between stimulator and responder resulted in higher expansion rates (P,0.05) ( Figure 3C ). Mismatches at other HLA genes did not significantly correlate with expansion efficiency (data not shown).
For polyclonal stimulation we used CD3 and CD28 triggering, and we compared anti-CD3+ anti-CD28 mAb coated microbeads with platebound anti-CD3+ soluble anti-CD28 mAb stimulation. For primary expansion of Treg, higher proliferation rates were achieved with beads as compared to platebound anti-CD3+ soluble anti-CD28 mAb ( Figure 4A ). Cell yield after expansion of Treg with either stimulation mode, using optimal dosage, was higher for anti-CD3+ anti-CD28 bead stimulation as compared to platebound anti-CD3+ soluble anti-CD28 stimulation ( Figure 4B ). To explain these differences, we assessed cell division and survival in Treg cultures for both stimuli ( Figure 4C ). Upon stimulation with anti-CD3+ anti-CD28 mAb coated beads, the majority of cells were triggered to proliferate as determined by CFSE dilution. Expression of 7AAD, a marker for late apoptotic cells, was low. Bcl-2, an anti-apoptotic protein, was expressed by 70-85% of the cells. Further gating revealed that the dividing cell population specifically expressed Bcl-2. Upon stimulation with platebound anti-CD3+ soluble anti-CD28 mAb, and independent of the concentration used, a large portion of cells was not triggered to proliferate. Again 7AAD staining was low. The percentage of cells that expressed Bcl-2 was lower as compared to cells stimulated with anti-CD3+ anti-CD28 beads, this correlated with the percentage of dividing cells. The results indicate that the lower cell yield after stimulation of Treg with platebound anti-CD3+ soluble anti-CD28 mAb is merely caused by less efficient triggering of Treg proliferation, and is not the result of enhanced cell death.
These experiments were also conducted for secondary polyclonal stimulation. In this situation, platebound anti-CD3+ soluble anti-CD28 stimulation was superior as a secondary stimulus as compared to anti-CD3+ anti-CD28 microbead stimulation ( Figure 5A ). Expansion cultures stimulated with platebound anti-CD3+ soluble anti-CD28 yielded more Treg as compared to cultures stimulated with anti-CD3+ anti-CD28 beads ( Figure 5B ). Attempting to explain these findings, we again assessed cell division and survival in Treg cultures using both stimuli ( Figure 5C ). In contrast to the results after primary stimulation, both polyclonal stimuli now induced massive proliferation as assessed by CFSE dilution. Also, both 7AAD staining and Bcl-2 expression were comparable between Treg cultures stimulated with either anti-CD3+ anti-CD28 beads or platebound anti-CD3+ soluble anti-CD28 mAb. The data shown in Figure 5 were obtained with Treg primed with anti-CD3+ anti-CD28 beads, similar results were observed when alloantigen primed Treg were used (data not shown). Overall, these data prompted us to use platebound CD3+ soluble CD28 mAb for polyclonal Treg restimulation in further experiments.
Several reports have described the use of high dose IL-2 in Treg expansion protocols [16, 17] . Our laboratory and others have shown that combination of IL-2 and IL-15 increases Treg proliferation [21, 27] . We thus added titrated concentrations of IL-2 (range 12,5 U/ml to 200 U/ml) with a fixed concentration of IL-15 (10 ng/ml) to Treg cultures to determine the optimal IL-2 dose in our system. Concentrations of 25 U/ml or higher gave similar results in terms of Treg yield (data not shown). We therefore chose to use 25 U/ml IL-2 in combination with 10 ng/ ml IL-15 for expansion experiments.
To determine the optimal cycle length, cell numbers were counted at several time points during primary and secondary expansion cycles. Expansion values were calculated and are depicted in Figure 6 . In primary Treg expansion cycles with either alloantigen or polyclonal stimulation, cultures reached maximal cell numbers after 10-12 days. In secondary expansion cycles with alloantigen stimulation, peak cell numbers were found at day 10. In secondary expansion cycles with polyclonal stimulation, peak cell numbers were found at day 10 if cells had been primed with alloantigen. However, when Treg had been primed with polyclonal stimulation, a plateau in cell numbers in a secondary polyclonal stimulation cycle was reached around day 7. Since our prime interest was to obtain alloantigen-specific Treg, the strategy comprising two subsequent cycles with polyclonal stimulation actually served as a control. Consequently, we standardized the expansion cycle length at 10 days for all strategies.
Cell yield after Treg expansion with combined alloantigen and polyclonal stimulation strategies
Having optimized the conditions for the primary and secondary expansion cycles, we now isolated Treg and Tconv and subsequently applied multiple expansion cycles according to the strategies depicted in Figure 1 . Average Treg expansion values are shown in Figure 7 . Contrary to our expectation that stimulation cycles with alloantigen would provide lower cell yields as compared to cycles of polyclonal expansion, Treg numbers obtained after each of the four expansion strategies were similar (average fold expansion 780, SD 300, p = 0.71, N = 4).
Phenotypic characterization of expanded Treg
A potential risk of Treg expansion is the outgrowth of contaminating cell types such as CD8 pos T cells or NK-cells. In our experiments, we did not find major contaminations, since typically .90% of the expanded cells were CD4 pos T cells. The pos cells. The expression of CD70, the ligand for CD27, was reversely correlated with CD27 expression. CD62L is also described as a marker for Treg with high suppressive potency [24] . Whereas expression of CD62L was lost on expanded Tconv cells, a substantial portion of Treg retained expression of this marker.
Functional characterization of expanded Treg
Treg retain anergic properties after expansion. One of the hallmarks of Treg is their anergic (hyporesponsive) behavior in vitro. Treg retained their anergic state after expansion, irrespective of the strategy employed, while in contrast Tconv were not anergic. Indeed, Treg did not proliferate upon stimulation in absence of exogenous T cell growth factors, while addition of IL-2 restored the proliferative capacity ( Figure 9 ).
Expanded Treg show enhanced suppressive capacity and can acquire full antigen-specificity within two expansion cycles. The main characteristics of alloantigen-specific Treg should be their strong suppressive capacity when stimulated by target antigen (in transplantation settings this would be donor antigen), in parallel with a lack of suppressive activity in the case of stimulation by other antigens such as fully HLA mismatched third party alloantigen. To assess suppressive capacity, we used both the classic [ 3 H]Thymidine incorporation co-culture suppression assay as well as a CFSE based assay. The latter is used because in some instances it is difficult to draw clear conclusions from the [ 3 H]Thymidine assay when using multiple cell populations. Figure 10 shows that highly antigen-specific Treg were obtained in two situations. Treg expanded with two cycles of alloantigen stimulation showed very high suppressive activity in target antigen driven MLR (.90% suppression in all ratios tested, Figure 10A ) and hardly any suppression of third party antigen driven MLR. The cells obtained after the strategy starting off with a primary allostimulation, followed by secondary polyclonal stimulation, also yielded potent Treg with high antigen-specificity, as indicated by strong suppression of target antigen driven responses (.50% suppression with Tresp:Treg ratios of 16:1 or lower, Figure 10A ) and low inhibition of third party HLA mismatched allostimulated MLR. Importantly, these data show that under these circumstances a very high degree of antigen-specificity can already be obtained after two cycles of expansion. This is relevant since we have noticed that multiple expansion cycles, irrespective of the mode of stimulation, can lead to reduced suppressive capacity, cell exhaustion, and subsequent cell death (data not shown). The expansion strategy starting off with a primary polyclonal stimulus followed by a secondary alloantigen stimulus yielded very potent suppressors, showing .90% suppression of target antigen driven MLC at all ratios tested (highest ratio tested 32:1, Figure 10A ). However, this cell population was still capable of suppression in third party alloantigen driven responses, albeit at a much lower efficiency than target antigen driven responses (.50% suppression at Tresp:Treg ratios 2:1 or lower, Figure 10A ), indicating a strong enrichment Treg specific for target antigen, but incomplete exclusion of Treg with other specificities. As expected, Treg expanded with two cycles of polyclonal stimulation showed suppression of both target antigen as well as 3 rd party alloantigen driven MLR to a similar, moderate degree (.50% suppression at 8:1 and 4:1 or lower, respectively, Figure 10A ). Treg displayed similar suppressive activity in CFSE suppression assays, while expanded Tconv were not suppressive ( Figure 10B ). Note that in the [ counts observed after titration of high numbers of expanded Tconv are not indicative of suppression per se, but rather a result of the very early proliferation of already primed Tconv cells in the co-culture. These cells heavily compete for medium components with the naïve Tresp cells that respond later in time. Tconv present in substantial numbers may indeed lead to distinct culture kinetics with an earlier proliferation peak and a net result of lower counts at day 5.
In summary, optimal results were obtained with Treg expansion in two subsequent cycles of alloantigen stimulation: efficient increases in cell numbers, yielding highly potent and strictly antigen-specific Treg. The success of Treg expansion with alternated alloantigen and polyclonal stimulation depends on the order of the stimulation cycles. When Treg are expanded by a primary alloantigen stimulus followed by a secondary polyclonal stimulus, cells expand efficiently and show highly potent, strictly antigen-specific suppressive capacity. The reverse strategy with a primary polyclonal stimulus and a secondary alloantigen stimulus, yield high numbers of cells, and enrichment for target antigenspecific Treg. However, Treg specific for other antigens are still present. As expected, two cycles of polyclonal stimulation yielded high numbers of Treg. These cells were suppressive, but no enrichment for alloantigen-specific Treg had taken place.
Discussion
High numbers of Treg will be needed for effective Treg immunotherapy in humans to facilitate tolerance in patients with auto-immunity or after transplantation. Ex vivo Treg expansion can provide the solution to obtain these high numbers. Therapeutic efficiency can be improved by selecting for targetantigen reactive Treg, as indicated by preclinical mouse models designed to study the prevention of autoimmunity [12] [13] [14] and graft-versus-host disease [4, 6, 7] . At the same time, exclusion of Treg with specificities for other antigens lowers the risk for unwanted non-specific immune suppression, thus decreasing the risk on opportunistic infections and tumor growth.
Information on strategies for large scale antigen-specific expansion of human Treg is scant [22] , as previous studies on ex vivo Treg expansion have primarily focused on polyclonal stimulation of Treg [16] [17] [18] [19] [20] [21] . In the current report, we demonstrate the ex vivo generation of Treg with direct alloantigen-specificity from human naturally occurring CD4 pos CD25 high Treg in as little as two stimulation cycles, requiring primary stimulation with HLA-mismatched allogeneic stimulator cells and IL-2 plus IL-15. Experiments were performed with alternating allogeneic and polyclonal (anti-CD3 anti-CD28 mAb) stimulation to define the ex vivo conditions resulting in optimal enrichment of alloantigenspecific Treg and high cell yield.
Naturally occurring CD4 pos CD25 high Treg display a polyclonal TCR V-beta pattern [28] . Stimulation of this polyclonal Treg population with allogeneic stimulator APC has been shown to specifically activate alloantigen-reactive Treg in mice [1, 4, 6, 7, 29, 30] and humans [27] . Thus, these studies indicate that it is feasible to generate alloantigen-specific Treg from the naturally occurring high Treg isolation by a magnetic bead based method is now feasible using the CliniMACS system [31, 32] , albeit that Treg purity is suboptimal (50-60%). Our recent data on expansion of CliniMACS isolated Treg confirms that the results reported here can indeed be extrapolated to clinical grade purification (unpublished observations). Clearly, with regard to purity of the starting population magnetic bead isolation is inferior to FACS sorting, but this latter method is not readily available for GMP purposes. We obtained with high purity FACS sorted Treg similar results regarding antigen specificity, but with lower expansion rates and higher overall suppressive capacity (unpublished observations).
To design a successful strategy for obtaining high numbers of alloantigen-specific Treg, we hypothesized that it might be beneficial to combine ex vivo expansion cycles applying polyclonal stimulation, to boost expansion, and cycles applying alloantigen stimulation, to selectively stimulate alloantigen-specific Treg. Our data show that a high degree of alloantigen-specificity could be obtained in as little as two cycles of expansion. To increase alloantigen-specificity even more, it would be an option to repeat alloantigen expansion stimulation for multiple cycles, which in theory would progressively enrich for strictly antigen-specific Treg. However, if Treg populations were expanded for more than two expansion cycles, we observed a loss of suppressive capacity and high cell death (unpublished results).
Although highest cell yields were expected after expansion with two polyclonal stimulation cycles, our data showed similar cell numbers for all strategies. This result may in part be due to the fact that we opted for a standardized 10 day culture cycle. This choice was made based on the fact that strategies comprising one or more alloantigen stimulation cycles showed optimal expansion at day 10. However, expansion of cells in a second subsequent polyclonal stimulation cycle reached an optimum at day 7, cell death occurred thereafter.
Of note, the strategies described in this report generate Treg with direct alloantigen-specificity. These cells may be especially of benefit for patients receiving an HLA mismatched stem cell graft, where this route of alloantigen-reactivity is important in graft versus host pathology [33] . Although transplantation centers pursue a high degree of HLA-matching to prevent harmful reactions, HLA-locus mismatched and haploidentical transplants are increasingly being performed [34] . In these cases current immunosuppressive regimen may benefit from the addition of an antigen-specific component. In solid organ transplantation, next to direct alloantigen recognition, the indirect route of alloantigen presentation clearly contributes to graft rejection [35] . With this in mind, it was recently shown, that it is also feasible to obtain Treg with indirect alloantigen-specificity by stimulation with autologous dendritic cells pulsed with allo-HLA-peptides [36] .
Recently, the first clinical trials on Treg immunotherapy have been initiated; in these studies, either CliniMACS isolated CD4 pos CD25 high Treg or ex vivo manipulated CD4 pos T cell lines containing induced regulatory Tr1 cells are being infused in patients receiving stem cell transplantations [22] . So far, no effects have been reported. In summary, this study has shown that it is feasible to obtain human functional alloantigen-specific Treg in large numbers for immunotherapeutic purposes. This may be a valuable aid in the clinical application of Treg, aiming at clinical tolerance to selected antigens, while minimizing general immune suppression.
Materials and Methods
Treg expansion strategies
To determine the optimal expansion strategy for obtaining high numbers of functionally active human alloantigen-specific Treg from CD4 pos CD25 high Treg, we devised four different strategies, consisting of two subsequent cycles of expansion with alternated polyclonal and alloantigen-specific stimulation (Figure 1 ).
Cell preparation / isolation
Buffy coats were purchased from Sanquin bloodbank, Nijmegen, The Netherlands. These buffy coats were obtained from healthy human donors upon written informed consent with regard to scientific use.
The current study did not require approval from an ethical committee according to the Dutch Medical Research Involving Human Subjects Act (WMO). PBMC were isolated by density gradient centrifugation (Lymphoprep, Nycomed Pharma, Roskilde, Denmark). CD4 pos T cells were negatively selected using mAbs directed against CD8 (RPA-T8), CD14 (M5E2), CD16 (3G8), CD19 (4G7), CD33 (P67.6), CD235a (GA-R2(HIR2) (all from BD Biosciences, San Jose, CA), and CD56 (MOC-1) (Dako, Glostrup, Denmark) combined with sheep-anti-mouse-IgG coated magnetic beads (Dynal Biotech, Oslo, Norway), routinely resulting in a .90% pure CD4 pos T cell fraction. CD25 high Treg and CD25 neg conventional T cells were separated by MACS-sorting, using 10 ml anti-CD25 magnetic microbeads / 10 7 CD4 pos cells (Miltenyi Biotec, Bergisch Gladbach, Germany). HLA typing was performed by serological and DNA based techniques according to international (ASHI/EFI) standards [37] .
CD4
pos CD25 high Treg expansion
Cell cultures were performed in 96-well round bottom plates with culture medium consisting of RPMI 1640 supplemented with pyruvate (0.02 mM), penicillin (100 U/ml), streptomycin (100 mg/ ml), and 10% human pooled serum (HPS), in a 37 o C, 95% humidity, 5% CO 2 incubator.
To optimize Treg expansion conditions, the mode and strength of stimulation, exogenous cytokine concentration, and expansion cycle length were varied in early experiments, as reported in the Results section. For assessment of cell division using CFSE, 1-5610 6 cells were labeled with 0.5 mM CFDA-SE (Molecular Probes) prior to stimulation. The final expansion protocols are described below.
For primary and secondary cycle alloantigen-specific expansion, 2.5610 4 T cells were cultured with 10 5 irradiated (30 Gy) HLA mismatched allogeneic PBMC (target alloantigen, ratio alloPBMC:Treg = 4:1).
For first cycle polyclonal expansion, 2.5610 4 T cells were cultured with 1.25610 4 anti-CD3+ anti-CD28 coated microbeads (Dynal Biotech). For secondary cycle polyclonal expansion, 2.5610 4 Treg were cultured with 5 mg/ml platebound anti-CD3 (UCHT1, BD Biosciences, 4 hours in PBS in incubator) plus 1 mg/ml soluble anti-CD28 (CD28.2, BD Biosciences).
Exogenous rhIL-2 (25 U/ml, Chiron, Amsterdam, the Netherlands) and rhIL-15 (10 ng/ml BioSource International, Camarillo, CA) were added to all expansion cultures. Wells were split and fresh medium containing cytokines was added every 3 days. After 10 days, the cells were harvested, washed and rested for 2 days in 5% HPS culture medium with 5 ng/ml rhIL-15 before analysis or further expansion. In all experiments, Tconv were included as control.
Flow cytometry
The phenotype of cells was analyzed by five-color flow cytometry (FC500, Beckman Coulter, Fullerton, CA). For cell surface staining, the following conjugated mAbs were used: CD25(M-A251)-PE, CD70(Ki-24)-PE, CD127(hIL-7R-M21)-AlexaFluor647 (BD Biosciences), CD27(M-T271)-FITC (Dako), CD4-(SFCI12T4D11)-PCy7 For assessment of cell division using CFSE dilution, naïve autologous 5-10610 6 CD4 pos CD25 neg T responder cells were labeled with 1 mM CFDA-SE (Molecular Probes) prior to stimulation, and allogeneic stimulator PBMC were labeled with 2 mM PKH26 (Sigma-Aldrich). 
Co-culture suppression assay
